Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psoriasis comorbidities.

Alice B Gottlieb1, Chun Chao, Frank Dann

  • 1Tufts-New England Medical Center, Boston, MA 02111-1533, USA. agottlieb@tufts-nemc.org

The Journal of Dermatological Treatment
|February 15, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study.

Annals of the rheumatic diseases·2026
Same author

Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality.

Dermatology and therapy·2026
Same author

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

JAMA dermatology·2026
Same author

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Hidradenitis Suppurativa Patients Experience a Significant Musculoskeletal Symptom Burden: A Quality Improvement Initiative Using the IDEOM MSK-Q.

The Journal of clinical and aesthetic dermatology·2025
Same author

Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.

Dermatology and therapy·2025
Same journal

Active surveillance for basal cell carcinoma: experiences of patients and proxies.

The Journal of dermatological treatment·2026
Same journal

Severe cutaneous adverse reactions associated with systemic antibiotics in acne vulgaris: a systematic review.

The Journal of dermatological treatment·2026
Same journal

Intralesional human papillomavirus vaccination for cutaneous verrucae: a systematic review and meta-analysis of therapeutic efficacy.

The Journal of dermatological treatment·2026
Same journal

JAK inhibitor-associated acne: a mechanistic paradox with important clinical implications.

The Journal of dermatological treatment·2026
Same journal

Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a <i>post hoc</i> analysis of a phase-III trial.

The Journal of dermatological treatment·2026
Same journal

Predictors of optimal disease control in atopic dermatitis with abrocitinib: a real-world study.

The Journal of dermatological treatment·2026
See all related articles

Psoriasis, a chronic inflammatory disease, is linked to serious health issues like metabolic syndrome and cardiovascular disease. Chronic inflammation and factors like tumor necrosis factor-alpha play a key role in these interconnected conditions.

Area of Science:

  • Dermatology
  • Immunology
  • Cardiology
  • Endocrinology

Background:

  • Psoriasis is a chronic inflammatory disease impacting quality of life and productivity.
  • It is associated with significant comorbidities, including malignancy, depression, cardiovascular disease, and metabolic syndrome.
  • Psoriasis patients exhibit higher rates of metabolic syndrome components: obesity, dyslipidemia, and insulin resistance.

Purpose of the Study:

  • To explore the link between psoriasis and its emerging comorbidities.
  • To elucidate the role of chronic inflammation and molecular mechanisms in psoriasis-associated metabolic dysfunction.
  • To review the impact of tumor necrosis factor antagonists in treating these conditions.

Main Methods:

  • Literature review of studies on psoriasis and its comorbidities.

Related Experiment Videos

  • Analysis of molecular pathways involved in psoriasis pathogenesis and metabolic dysregulation.
  • Examination of clinical trial data on biologic therapies.

    • Main Results:

    • Psoriasis shares underlying chronic inflammation with metabolic syndrome and cardiovascular disease.
    • Increased levels of pro-inflammatory factors, such as tumor necrosis factor-alpha, are implicated in metabolic dysfunction.
    • Tumor necrosis factor antagonists show promise in managing psoriasis comorbidities.

    Conclusions:

    • The chronic inflammation in psoriasis is a key driver of associated metabolic and cardiovascular comorbidities.
    • Targeting inflammatory pathways may offer therapeutic benefits for both psoriasis and its related health issues.
    • Further research is warranted to fully understand and manage these complex interrelations.